Table 1 Patient baseline and treatment characteristics; patients still under therapy are not included in follow-up/outcome analysis
characteristic | range | |
|---|---|---|
median age (years), n = 18 | 57 | 44 - 69 |
median follow-up (months), n = 14 excluding pts under treatment | 17.4 | 6.5 - 30 |
deceased (pts) | 1 | |
male (pts) | 16 | |
female (pts) | 5 | |
Site (n = 18) | ||
palate (pts) | 2 | |
oropharynx | 7 | |
hypopharynx | 6 | |
larynx | 3 | |
Stage (n = 18) | ||
T2 | 3 | |
T3 | 8 | |
T4 | 7 | |
N0 | 2 | |
N2b | 4 | |
N2c | 11 | |
N3 | 1 | |
therapy (n = 14) | ||
median dose (cervical lymph nodes)/Gy | 50 | 49 - 51 |
median dose (primary and involved nodes)/Gy | 20 | 19 - 24 |
median total dose/Gy | 70 | 69 - 74 |